Every 8-K that Lakewood-Amedex Biotherapeutics Inc. (LABT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LABT filings page.
Lakewood-Amedex Biotherapeutics Inc. furnished an investor presentation describing its Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials aimed at drug-resistant infections and antimicrobial resistance. The deck highlights Nu-3, a topically delivered antimicrobial gel in Phase 2-ready development for infected diabetic foot ulcers (iDFU), with supporting preclinical and early clinical data, safety profile, and a U.S.- and internationally focused Phase 2/Phase 3 regulatory strategy.
The presentation also outlines a development pipeline beyond Nu-3, a planned Phase 2a/2b iDFU trial with key 2026 milestones, and an intellectual property estate of 101 patents with protection extending up to 2044, along with details on the competitive landscape and experienced leadership team.
Lakewood-Amedex Biotherapeutics Inc. is implementing a 1-for-10 reverse stock split of its common stock. The change becomes effective at 4:01 p.m. Eastern Time on June 19, 2026, and the shares will begin trading on a split-adjusted basis on Nasdaq on June 22, 2026 under the existing symbol LABT.
Every ten shares of common stock will be exchanged for one share, with any fractional positions rounded up to the next whole share. The company is also proportionately reducing its authorized common stock to 12,500,000 shares and making equitable adjustments to equity awards, preferred stock, warrants and related exercise or conversion prices. The common stock has been assigned a new CUSIP number, 51255A201.
Lakewood-Amedex Biotherapeutics Inc. appointed Joseph Tucker, Ph.D., a veteran biotechnology executive and current CEO of Enveric Biosciences, to its Board of Directors effective April 24, 2026. He will serve until the company’s 2027 annual meeting of stockholders, and will also join the Finance, Audit and Risk, Compensation, and Corporate Governance and Nominating Committees.
Under a board agreement, Dr. Tucker will attend at least two and up to four board meetings per year and be available for ad-hoc consultations. He will receive $6,000 per quarter in common stock and has been granted 33,784 warrants to purchase common stock at $10.00 per share, vesting in four equal tranches between October 2026 and April 2028 with a 10‑year term. The company highlights his experience raising over $100 million, leading public biotech companies, and executing IPOs, mergers, and acquisitions.